价格

Global Blood Therapeutics, Inc.

ACTIVE

181 Oyster Point Blvd, South San Francisco, California, 美国www.gbt.comPublic457 名员工成立于: 2011-02-01

别名:

gbt

global blood therapeutics, inc, a subsidiary of pfizer inc.

隶属于 PFIZER INC.

概览

试验阶段分布

阶段

试验数

占比

1 期

63.9%

3 期

25.0%

2 期

8.3%

试验状态分布

进行中（未招募）

63.9%

已完成

11.1%

尚未招募

11.1%

招募中

8.3%

暂停

2.8%

Unknown

2.8%

相关临床试验

该机构主办的试验（36）

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

A Phase 2/3 Study in Adult and Pediatric Participants with SCD

A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease

Open-Label Extension of Voxelotor

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises

An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial

A Phase 2/3 Study in Adult and Pediatric Participants with Sickle Cell Disease (SCD)

第 1 页，共 5 页

药物批准

按机构分类的批准

FDA

Food and Drug Administration

药物批准

近期批准

资讯

暂无资讯文章

返回机构列表